Global Autoimmune Gastrointestinal Dysmotility Market – Industry Trends and Forecast to 2030

Autoimmune Gastrointestinal Dysmotility Market Analysis and Size

The autoimmune gastrointestinal dysmotility market is experiencing significant growth, driven by increasing awareness about autoimmune diseases, advancements in diagnostic techniques, and the rising prevalence of gastrointestinal disorders. The market is witnessing a surge in research and development activities aimed at developing novel therapies and improving existing treatment options.  With the increasing focus on personalized medicine and the development of targeted therapies, the  market is expected to continue expanding in the coming years.

Data Bridge Market Research analyzes that the global autoimmune gastrointestinal dysmotility market was valued at USD 28.00 billion in 2022 and is expected to reach USD 128.54 billion by 2030, registering a CAGR of 18.7% during the forecast period of 2023-2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Autoimmune gastrointestinal dysmotility (AGID) refers to a condition in which the immune system mistakenly targets and attacks the nerves or muscles of the gastrointestinal (GI) tract, leading to disruptions in the normal movement and function of the digestive system. The GI tract includes organs such as the esophagus, stomach, small intestine, and large intestine, and their coordinated movement is essential for the proper digestion and absorption of nutrients.

Global Autoimmune Gastrointestinal Dysmotility Market Dynamics

Drivers

• Immunological Factors

In autoimmune disorders, including AGID, the immune system mistakenly targets and attacks the nerves or muscles in the digestive tract, leading to impaired motility. As researchers gain a better understanding of the immunological mechanisms underlying autoimmune gastrointestinal dysmotility, they can develop targeted therapies that specifically modulate the immune response. This has led to the development of biologics and other immunomodulatory agents that show promise in treating autoimmune gastrointestinal dysmotility by suppressing the autoimmune response and reducing inflammation in the gastrointestinal tract. Immunological factors play a crucial role in driving the market.

• Environmental Triggers

Environmental factors such as diet, infections, and exposure to toxins can trigger or exacerbate autoimmune responses in susceptible individuals. For example, certain dietary components have been linked to increased gut permeability and inflammation, which can contribute to autoimmune gastrointestinal dysmotility. Understanding these environmental triggers can help in developing preventive strategies and identifying high-risk individuals, thereby driving the demand for diagnostic tests and therapies for autoimmune gastrointestinal dysmotility.

Opportunities

• Personalized Medicine

As per the understanding of the genetic and molecular factors influencing autoimmune disorders deepens, there is an opportunity to develop personalized treatment approaches. Personalizing therapies based on an individual's genetic makeup, immunological profile, and other factors could lead to more effective and targeted interventions.

• Telemedicine and Remote Monitoring

Advances in telemedicine and remote monitoring technologies can improve access to healthcare for individuals with AGID. Remote monitoring of symptoms and virtual consultations can enhance patient care, particularly for those who may face challenges with physical mobility., this creates new opportunities for the market.

Restraints/Challenges

• Complexity of Diagnosing AGID

Diagnosing AGID can be challenging due to the diversity of symptoms and the lack of specific diagnostic markers. The condition may mimic other gastrointestinal disorders, leading to misdiagnosis or delayed diagnosis. As a result, individuals with AGID may experience prolonged periods of uncertainty and frustration. There is currently no cure for AGID, and treatment options are often aimed at managing symptoms and modulating the immune response. Immunosuppressive medications may be used, but they can have side effects and may not be universally effective, which is a major challenge for the market.

This autoimmune gastrointestinal dysmotility market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the autoimmune gastrointestinal dysmotility market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In April 2022, TheraCell Inc., a leading allograft solution company, today announced that Isto Biologics have acquired it, a leader in surgical-based, orthobiologic regeneration technologies and cell-based therapies
• In October 2020, Evoke Pharma, Inc. and EVERSANA announced the commercial launch of Gimoti (metoclopramide) nasal spray for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis

Global Autoimmune Gastrointestinal Dysmotility Market Scope

The autoimmune gastrointestinal dysmotility market is segmented on the basis of product type, compound, application and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Plasma Exchange
• Medications
• Immunotherapy

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Global Autoimmune Gastrointestinal Dysmotility Market Regional Analysis/Insights

The autoimmune gastrointestinal dysmotility market is analyzed and market size insights and trends are provided by country, product type, compound, application and end-user as referenced above.

The countries covered in the market report are U.S., Canada, Mexico, Germany, Sweden, Poland, Denmark, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa , Brazil, Argentina and rest of South America.

North America is expected to dominate and be the highest growing region in the market due to it increasing rapidly over the past few years due to the expansion of the major players' production capacities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

The autoimmune gastrointestinal dysmotility market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for autoimmune gastrointestinal dysmotility market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the autoimmune gastrointestinal dysmotility market. The data is available for historic period 2010-2020.

Competitive Landscape and Global Autoimmune Gastrointestinal Dysmotility Market Share Analysis

The autoimmune gastrointestinal dysmotility market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to autoimmune gastrointestinal dysmotility market.

Some of the major players operating in the autoimmune gastrointestinal dysmotility market are:

• YCELLBIO MEDICAL (South Korea)
• Zimmer Biomet (U.S.)
• Stryker (U.S.)
• ROCKY MOUNTAIN BIOLOGICALS (U.S.)
• Regen Lab SA (Switzerland)
• TERUMO BCT, INC. (U.S.)
• GLOFINN (Finland)
• ExaTech Inc. (U.S.)
• EmCyte Corporation (U.S.)
• ThermoGenesis Holding, Inc. (U.S.)
• Octapharma Brasil Ltda (Brazil)
• Dr PRP USA LLC (U.S.)
• Isto Biologics (U.S.)
• Arthrex, Inc. (U.S.)
• Terumo Corporation (Japan)
• Cascade Medical. (U.S.)
• Grifols, S.A. (Spain)

SKU-69185